C4 Therapeutics, INC Form 4 insider transactions

Leonard Reyno, Chief Medical Officer of C4 Therapeutics, Inc., reported multiple transactions in common stock on July 10, 2026.

C4 Therapeutics, Inc. reports that Director Owen Hughes acquired 62,000 stock options with an exercise price of $4.25.

C4 Therapeutics Director Steven L. Hoerter acquired 62,000 stock options with an exercise price of $4.25.

C4 Therapeutics, Inc. reports that Director Utpal Koppikar was granted 62,000 stock options with an exercise price of $4.25, vesting in full by June 24, 2027.

C4 Therapeutics Director Kenneth Carl Anderson acquired 62,000 stock options with an exercise price of $4.25, vesting on June 24, 2027, or the next annual meeting.

C4 Therapeutics, Inc. reports that Director Ronald Harold Wilfred Cooper acquired 62,000 stock options with an exercise price of $4.25.

Laura Bessen, a Director at C4 Therapeutics, Inc., acquired 62,000 stock options with an exercise price of $4.25.

C4 Therapeutics Director Stephen Fawell acquired 62,000 stock options with an exercise price of $4.25, vesting in full by June 24, 2027, or the next annual meeting.

C4 Therapeutics Director Donna Roy Grogan acquired 62,000 stock options with an exercise price of $4.25, vesting in full by June 24, 2027, or the next annual meeting.

C4 Therapeutics Director Kenneth Carl Anderson exercised stock options for 1,070 shares of common stock on June 1, 2026.

C4 Therapeutics, Inc. reports a director's receipt of common stock as compensation, with detailed beneficial ownership information.

C4 Therapeutics, Inc. reports that Director Donna Roy Grogan acquired 5,370 shares of common stock on April 1, 2026, as part of her compensation.

C4 Therapeutics' Chief Medical Officer, Leonard Reyno, reported the sale of 10,000 shares of common stock at $2.22 per share.

C4 Therapeutics Director Donna Roy Grogan acquired 7,513 shares of common stock at $1.93 per share, increasing her direct beneficial ownership to 66,142 shares.

C4 Therapeutics Director Kenneth C. Anderson acquired 5,958 shares of common stock at $1.93 per share as part of his non-employee director compensation.

C4 Therapeutics' Chief Scientific Officer, Paige Mahaney, reported the vesting of restricted stock units and subsequent tax-related share withholding.

C4 Therapeutics Director Kenneth Anderson acquired 5,349 shares of common stock at $2.15 per share, opting for equity in lieu of cash compensation.

C4 Therapeutics Director Donna Roy Grogan acquired 6,740 shares of common stock at $2.15 per share, opting for equity in lieu of cash compensation.

C4 Therapeutics' Chief Financial Officer, Kendra Adams, reported the acquisition of common stock through RSU vesting and subsequent disposition for tax obligations.

C4 Therapeutics, Inc.'s Chief Medical Officer, Leonard Reyno, reported the vesting of restricted stock units and associated tax withholding, resulting in a net increase in his beneficial ownership.

C4 Therapeutics, Inc.'s Chief Medical Officer, Leonard Reyno, reported the withholding of 7,382 shares of common stock to cover tax obligations related to restricted stock unit vesting.

C4 Therapeutics, Inc. Director Kenneth Carl Anderson acquired 7,616 shares of common stock at $1.51 per share on July 1, 2025, as part of his non-employee director compensation.

Donna Roy Grogan, a Director at C4 Therapeutics, Inc., acquired 9,609 shares of common stock on July 1, 2025, as part of her non-employee director compensation, increasing her total beneficial ownership to 51,889 shares.

C4 Therapeutics, Inc. (CCCC) Director Utpal Koppikar was granted 35,500 stock options with an exercise price of $1.44, vesting over approximately one year.

C4 Therapeutics, Inc. Director Owen Hughes was granted 35,500 stock options with an exercise price of $1.44, vesting by June 2026.

C4 Therapeutics, Inc. Director Stephen Fawell was granted 35,500 stock options with an exercise price of $1.44, vesting by June 2026 or the next annual meeting.

C4 Therapeutics, Inc. Director Kenneth Carl Anderson was granted 35,500 stock options with an exercise price of $1.44, vesting upon the earlier of June 18, 2026, or the next annual stockholders' meeting.

C4 Therapeutics, Inc. Director Laura Bessen was granted 35,500 stock options with an exercise price of $1.44, vesting upon the earlier of June 18, 2026, or the next annual stockholders' meeting.

C4 Therapeutics, Inc. (CCCC) has reported that Director Donna Roy Grogan was granted 35,500 stock options with an exercise price of $1.44, vesting over approximately one year.

C4 Therapeutics, Inc. Director Ronald Harold Wilfred Cooper was granted 35,500 stock options with an exercise price of $1.44 per share, vesting over approximately one year.